Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

Assiut University100 enrolled

Overview

Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage . New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti\_EGFR ,anti\_angiogenic and kinase inhibitors .

Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti\_EGFR targeted therapy between left colon and rectal cancer

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Metastatic Colorectal Adenocarcinoma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. age above 18 2. Both sex 3. Performance status zero to one according to ECOG scale system 4. Histo-pathologial diagnosis adenocarcinoma of left colon or rectum. 5. Patients diagnosed with left colon and rectal cancer. 6. Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC. 7. Patients diagnosed with metastatic stage. 8. K-RAS wild type. Exclusion Criteria: 1. Second malignancy 2. Histo-pathological types other than adenocarcinoma. 3. Right colon cancer patients. 4. Patients refused receiving anti\_EGFR targeted therapy. 5. Patients with any abnormalities preventing to receive chemotherapy. 6. Early stages of colorectal cancer. 7. K-RAS mutant type.

Outcomes

Primary Outcomes

OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy

Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment

Time frame: Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022

Secondary Outcomes

Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.

Factors affecting response to targeted therapy

Time frame: The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.